Ivana G. Sullivan - Publications

Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRAS G12C NSCLC.

Journal: Scientific reports

Published: February 19, 2026

Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 01, 2025

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.

Journal: Nature communications

Published: May 23, 2025

CD274 (PD-L1) Polymorphisms as Predictors of Efficacy in First-Line Platinum-Based Chemotherapy for Extensive-Stage Small Cell Lung Cancer.

Journal: International journal of molecular sciences

Published: March 19, 2025

Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 05, 2024

Landscape and clinical implications of EGFR exon 20 insertions in non-small cell lung cancer patients.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 05, 2024

Commentary on A Pulmonary Nodule with an Unexpected Mutation Profile.

Journal: Clinical chemistry

Published: October 14, 2024

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study.

Journal: Frontiers in oncology

Published: October 12, 2024

Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 23, 2024

Clinical and economic impact of the advanced practice nurse in lung cancer patients receiving immunotherapy-based treatments: A quantitative study.

Journal: European journal of oncology nursing : the official journal of European Oncology Nursing Society

Published: August 05, 2024

ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer.

Journal: Pharmaceutics

Published: July 10, 2024

Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients.

Journal: Biomedicines

Published: March 06, 2024